Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
| ▸ | TUBB | P07437 | 1/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.44 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.44 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.44 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7656050 | 0.88 | KDM4E (0.51) | KDM4EPOLBGAACISD2HSD17B10 | |
| SCHEMBL6826509 | 0.86 | KDM4E (0.56) | KDM4EPOLBGAACISD2HSD17B10 | |
| SCHEMBL29033634 | 0.84 | KDM4E (0.49) | KDM4EPOLBTSHRSMN1; SMN2TUBB4A | |
| SCHEMBL1807423 | 0.84 | KDM4E (0.49) | KDM4EPOLBHSD17B10TSHRSMN1; SMN2 | |
| SCHEMBL6943414 | 0.83 | KDM4E (0.47) | KDM4EPOLBGAACISD2HSD17B10 | |
| SCHEMBL7655424 | 0.82 | KDM4E (0.49) | KDM4EPOLBGAACISD2HSD17B10 | |
| Hydrochloric Acid SCHEMBL20547016 | 0.82 | DPP4 (0.48) | KDM4EPOLBGAAUSP2SMN1; SMN2 | |
| SCHEMBL30251221 | 0.80 | KDM4E (0.67) | KDM4EPOLBGAACISD2HSD17B10 | |
| SCHEMBL12587644 | 0.80 | POLB (0.57) | KDM4EPOLBGAACISD2HSD17B10 | |
| SCHEMBL9559705 | 0.79 | KDM4E (0.45) | KDM4EPOLBGAATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105037279-A | 4-N substituted quinazoline derivants adopting pentadienone structure and preparation and application of 4-N substituted quinazoline derivants | UNIV GUIZHOU | 2015-11-11 | — | — | CN | disclosed |
| CN-102942529-B | 4-(4-substituted piperazine)-5,6,7-trialkoxy quinazoline type compound as well as preparation method and application of 4-(4-substituted piperazine)-5,6,7-trialkoxy quinazoline type compound | UNIV GUIZHOU | 2015-06-24 | — | — | CN | disclosed |
| US-8859571-B2 | Quinazoline compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859571-B2 | Quinazoline compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859571-B2 | Quinazoline compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2501233-B1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2501233-B1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-09-24 | — | — | EP | disclosed |
| CN-102711474-B | Quinazoline compounds | GLAXOSMITHKLINE LLC | 2014-09-10 | — | — | CN | disclosed |
| CN-102942529-A | 4-(4-substituted piperazine)-5,6,7-trialkoxy quinazoline type compound as well as preparation method and application of 4-(4-substituted piperazine)-5,6,7-trialkoxy quinazoline type compound | UNIV GUIZHOU | 2013-02-27 | — | — | CN | disclosed |
| CN-102875481-A | 4-[2-(substituted benzylidene) hydrazino]-5, 6, 7-trialkoxy quinazoline compound and preparation method and application | UNIV GUIZHOU | 2013-01-16 | — | — | CN | disclosed |
| CN-102711474-A | Quinazoline compounds | GLAXOSMITHKLINE LLC | 2012-10-03 | — | — | CN | disclosed |
| EP-2501233-A1 | QUINAZOLINE COMPOUNDS | GlaxoSmithKline LLC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-08-30 | — | — | US | disclosed |
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-08-30 | — | — | US | disclosed |
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-08-30 | — | — | US | disclosed |
| WO-2011056740-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011056740-A1 | QUINAZOLINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| CN-101463015-B | Preparation of 5,6,7-trialkoxy-N-aryl substituted-4-amino quinazoline derivative and compound synthesized thereby | UNIV GUIZHOU | 2010-12-08 | — | — | CN | disclosed |
| CN-101463015-A | Preparation of 5,6,7-trialkoxy-N-aryl substituted-4-amino quinazoline derivative and compound synthesized thereby | UNIV GUIZHOU (CN) | 2009-06-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220588-A1 | QUINAZOLINE COMPOUNDS | NQO2, PRMT7, QDPR | KDM4E 2677/4885POLB 2726/4885GAA 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.